Literature DB >> 18810721

In-hospital management and mortality in elderly patients with non-ST-segment elevation acute coronary syndromes treated in centers without on-site invasive facilities.

Artur Dziewierz1, Zbigniew Siudak, Tomasz Rakowski, Joanna Zdzienicka, Dominika Dykla, Waldemar Mielecki, Jacek S Dubiel, Dariusz Dudek.   

Abstract

BACKGROUND: The purpose was to assess age-related differences in hospital management and mortality in non-ST-elevation acute coronary syndrome (NSTE ACS) patients treated conservatively, with a focus on the influence of aggressive pharmacological treatment on in-hospital clinical outcome.
METHODS: We identified 807 NSTE ACS patients treated conservatively in the 29 hospitals participating in the Krakow Registry of Acute Coronary Syndromes from February to March 2005 and from December 2005 to January 2006. Out of 807 patients' 32.1% were less than 65 years of age, 33% from 65 to 74, 30.5% from 75 to 84, and 5.3% >or= 85. For all patients, pharmacotherapy index based on the use of pharmacological treatment regimen during hospital stay was assessed. Each patient received 1 point for each of the following guideline-recommended drugs used: aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitor, LMWH, beta-blocker, ACE inhibitor/angiotensin II receptor blocker and statin - the range of points being from 0 to 7.
RESULTS: Significant age-related differences in baseline characteristics and pharmacotherapy index values were found. In-hospital mortality was higher in elderly patients (2.4% vs. 3.4% vs. 8.9% vs. 14.0%, respectively for age groups, p < 0.0001). Similarly, in non-shock patients and in patients with elevated cardiac markers, age-dependent differences in mortality were observed. Independent predictors of in-hospital death were: age, cardiogenic shock, elevated cardiac markers and pharmacotherapy index.
CONCLUSIONS: Advanced age is associated with less aggressive pharmacological treatment and higher in-hospital mortality in NSTE ACS patients remaining in community hospitals for conservative treatment. Broader implementation of current guidelines and more frequent invasive treatment might improve the outcomes of NSTE ACS patients regardless of age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810721

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  5 in total

1.  Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction.

Authors:  Artur Dziewierz; Dawid Giszterowicz; Zbigniew Siudak; Tomasz Rakowski; Jacek S Dubiel; Dariusz Dudek
Journal:  Clin Res Cardiol       Date:  2010-05-11       Impact factor: 5.460

2.  Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI.

Authors:  David D McManus; Joel Gore; Jorge Yarzebski; Frederick Spencer; Darleen Lessard; Robert J Goldberg
Journal:  Am J Med       Date:  2011-01       Impact factor: 4.965

3.  30-year trends in heart failure in patients hospitalized with acute myocardial infarction.

Authors:  David D McManus; Marcello Chinali; Jane S Saczynski; Joel M Gore; Jorge Yarzebski; Frederick A Spencer; Darleen Lessard; Robert J Goldberg
Journal:  Am J Cardiol       Date:  2011-02-01       Impact factor: 2.778

4.  Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes.

Authors:  Angel López-Cuenca; Miriam Gómez-Molina; Pedro J Flores-Blanco; Marianela Sánchez-Martínez; Andrea García-Narbon; Ignacio De Las Heras-Gómez; María J Sánchez-Galian; Esther Guerrero-Pérez; Mariano Valdés; Sergio Manzano-Fernández
Journal:  J Geriatr Cardiol       Date:  2016-01       Impact factor: 3.327

5.  National Trends in the Incidence, Management, and Outcomes of Heart Failure Complications in Patients Hospitalized for ST-Segment Elevation Myocardial Infarction.

Authors:  Manyoo Agarwal; Sahil Agrawal; Lohit Garg; Divyanshu Mohananey; Aakash Garg; Nirmanmoh Bhatia; Carl J Lavie
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.